JP2023542453A - Sars-cov-2阻害剤 - Google Patents

Sars-cov-2阻害剤 Download PDF

Info

Publication number
JP2023542453A
JP2023542453A JP2023502638A JP2023502638A JP2023542453A JP 2023542453 A JP2023542453 A JP 2023542453A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023542453 A JP2023542453 A JP 2023542453A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
acid sequence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542453A5 (cg-RX-API-DMAC7.html
Inventor
カオ,ロンシン
コベントリー,ブライアン
ゴレシュニク,インナ
ミラー,ローレン
ベイカー,デイビッド
コソドイ,リサ
ボーウェン,ジョン
カーター,ローレン
ケース,ジェームズ,ブレット
ダイアモンド,マイケル
エドマン,ナターシャ
ハント,アンドリュー
ジュウェット,マイケル,クリストファー
オゴハラ,カサンドラ,ジーン
パク,ヤン-ジュン
ラヴィチャンドラン,ラシュミ
スチュアート,ランス,ジョセフ
ヴィースラー,デイビッド
ヴォーゲリ,バスティアン
ウォールズ,アレクサンドラ,シー.
ウー,ケジア
ボイケン,スコット
ウエダ,ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St. Louis
Original Assignee
Washington University in St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St. Louis filed Critical Washington University in St. Louis
Publication of JP2023542453A publication Critical patent/JP2023542453A/ja
Publication of JP2023542453A5 publication Critical patent/JP2023542453A5/ja
Priority to JP2025136537A priority Critical patent/JP2025170319A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2023502638A 2020-07-14 2021-05-25 Sars-cov-2阻害剤 Pending JP2023542453A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136537A JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051474P 2020-07-14 2020-07-14
US63/051,474 2020-07-14
US202063067593P 2020-08-19 2020-08-19
US63/067,593 2020-08-19
PCT/US2021/034069 WO2022015418A1 (en) 2020-07-14 2021-05-25 Sars-cov-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136537A Division JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Publications (2)

Publication Number Publication Date
JP2023542453A true JP2023542453A (ja) 2023-10-10
JP2023542453A5 JP2023542453A5 (cg-RX-API-DMAC7.html) 2024-06-03

Family

ID=76808129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502638A Pending JP2023542453A (ja) 2020-07-14 2021-05-25 Sars-cov-2阻害剤
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Country Status (7)

Country Link
US (1) US20230250134A1 (cg-RX-API-DMAC7.html)
EP (1) EP4182027A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023542453A (cg-RX-API-DMAC7.html)
KR (1) KR20230038485A (cg-RX-API-DMAC7.html)
CN (1) CN116209672A (cg-RX-API-DMAC7.html)
AU (1) AU2021308208A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022015418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368631A4 (en) * 2021-07-07 2025-08-13 Univ Nat Corp Tokyo Medical & Dental PEPTIDE HAVING ANTIVIRAL ACTIVITY, ANTIVIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTIVIRAL AGENT
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
WO2025101453A1 (en) * 2023-11-07 2025-05-15 University Of Washington De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025221716A1 (en) * 2024-04-17 2025-10-23 University Of Washington Smart mhc: a de-novo designed platform for soluble expression of peptide-receptive class-i mhc in e. coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
CA3178016A1 (en) * 2020-05-27 2021-12-02 University Of Washington Modular and generalizable biosensor platform based on de novo designed protein switches

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG G ET AL.: "The first-in-class peptide binder to the SARS-CoV-2 spike protein", BIORXIV [ONLINE], JPN6025020251, 20 March 2020 (2020-03-20), ISSN: 0005597557 *

Also Published As

Publication number Publication date
CN116209672A (zh) 2023-06-02
WO2022015418A1 (en) 2022-01-20
EP4182027A1 (en) 2023-05-24
US20230250134A1 (en) 2023-08-10
KR20230038485A (ko) 2023-03-20
AU2021308208A1 (en) 2023-01-05
JP2025170319A (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
JP2025170319A (ja) Sars-cov-2阻害剤
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
WO2018028635A1 (zh) 一种寨卡病毒人源单克隆抗体及其应用
CN105073196B (zh) 呼吸道合胞病毒f蛋白表位
JP4902352B2 (ja) トランスフォーミング増殖因子β1(TGF−β1)との結合能を有するペプチド
CN113785052B (zh) 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途
WO2021170131A1 (zh) 可溶性ace2和融合蛋白,及其应用
JP2022530439A (ja) 組換えインフルエンザ抗原
KR20240012394A (ko) SARS-CoV-2 폴리펩타이드
CN115785232A (zh) 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
CZ303409B6 (cs) Zkrácený a mutovaný lidský chemokin
JP2023544169A (ja) 組換えace2-fc融合分子、その製造方法及びその使用
CA3153354A1 (en) Computational design of alpha(v) beta (6) integrin binding proteins
CA3181996A1 (en) Sars-cov-2 inhibitors
JP2022508619A (ja) ニューロメジンペプチドを使用して2型サイトカイン媒介性炎症を低減させる方法
CN115925892A (zh) 一种抗新型冠状病毒的中和抗体d9及其应用
CN117043176A (zh) 抗感染双环肽配体
US10766929B2 (en) De novo designed hemagglutinin binding proteins
US12617826B2 (en) CLEC2 fusion protein and uses thereof
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
WO2025101453A1 (en) De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025250851A1 (en) Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111